[8-K] IDEXX LABORATORIES INC /DE Reports Material Event
IDEXX Laboratories announced the election of Karen Peacock to its Board of Directors in a press release dated
IDEXX Laboratories ha annunciato l'elezione di Karen Peacock nel proprio Consiglio di Amministrazione in un comunicato stampa datato
IDEXX Laboratories anunció la elección de Karen Peacock para su Junta Directiva en un comunicado de prensa fechado el
IDEXX Laboratories는 Karen Peacock를 이사회에 선출했다고 2025년 10월 7일자 보도자료에서 발표했습니다. 선출은 위원회에 제출된 Form 8-K에서 공개되었으며 Exhibit 99.1로 첨부되어 있습니다. 이 서류는 Sharon E. Underberg, 수석 부사장 겸 총괄 고문 및 기업 서기가 서명했습니다. 이사 배경, 위원회 임명, 또는 이사회 구성의 변경에 관한 추가 세부 정보는 서류에 포함되어 있지 않습니다.
IDEXX Laboratories a annoncé l'élection de Karen Peacock à son conseil d'administration dans un communiqué daté du
IDEXX Laboratories kündigte die Wahl von Karen Peacock in ihren Vorstand in einer Pressemitteilung vom
IDEXX Laboratories أعلنت انتخاب Karen Peacock لعضويتها في مجلس الإدارة في بيان صحفي بتاريخ
IDEXX Laboratories宣布选举 Karen Peacock 为其董事会成员，公告日期为
- Karen Peacock was formally elected to the Board of Directors on
October 7, 2025
- None.
Insights
Board adds a new director; disclosure is routine and limited.
The filing records the formal election of Karen Peacock to the board and attaches the press release as Exhibit 99.1. This satisfies disclosure requirements for director appointments but provides no biographical or committee information to assess strategic impact.
The primary dependencies are the director's eventual committee roles and public background, which are not provided here. Monitor subsequent filings or the company website for a biographical disclosure and any related changes to board committees within the next quarter.
IDEXX Laboratories ha annunciato l'elezione di Karen Peacock nel proprio Consiglio di Amministrazione in un comunicato stampa datato
IDEXX Laboratories anunció la elección de Karen Peacock para su Junta Directiva en un comunicado de prensa fechado el
IDEXX Laboratories는 Karen Peacock를 이사회에 선출했다고 2025년 10월 7일자 보도자료에서 발표했습니다. 선출은 위원회에 제출된 Form 8-K에서 공개되었으며 Exhibit 99.1로 첨부되어 있습니다. 이 서류는 Sharon E. Underberg, 수석 부사장 겸 총괄 고문 및 기업 서기가 서명했습니다. 이사 배경, 위원회 임명, 또는 이사회 구성의 변경에 관한 추가 세부 정보는 서류에 포함되어 있지 않습니다.
IDEXX Laboratories a annoncé l'élection de Karen Peacock à son conseil d'administration dans un communiqué daté du
IDEXX Laboratories kündigte die Wahl von Karen Peacock in ihren Vorstand in einer Pressemitteilung vom
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
IDEXX LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission File Number) | (IRS Employer Identification No.) | ||
| of incorporation) |
(Address of principal executive offices) |
(ZIP Code) |
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Election of New Director. Effective October 6, 2025, the board of directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”) elected Karen Peacock as an independent Class I Director and appointed her as a member of its Compensation and Talent Committee and Finance Committee. To effect Ms. Peacock’s election as a Class I Director, the Board increased the number of Directors constituting the Board from ten to eleven and the number of Class I Directors from three to four. It is expected that Ms. Peacock will stand for election by stockholders as a Class I Director at the Company’s 2027 annual meeting of stockholders.
There are no related person transactions (or proposed related person transactions) with respect to Ms. Peacock reportable under Item 5.02(d) of Form 8-K and Item 404(a) of Regulation S-K since the beginning of the Company’s last fiscal year.
Ms. Peacock will receive the same compensation as is paid to the Company’s other non-employee Directors, as described in the section entitled “Corporate Governance – Non-Employee Director Compensation” in the Company’s Proxy Statement filed with the Securities and Exchange Commission on March 28, 2025, which description is incorporated herein by reference. The cash fee to be paid to Ms. Peacock in the fourth quarter of 2025 will be prorated to reflect the effective date of her election to the Board. Annual deferred stock unit or restricted stock unit and stock option grants were made to non-employee Directors on May 7, 2025, the date of the Company’s 2025 annual meeting of stockholders. Since Ms. Peacock was not serving as a Director at that time, such grants will be made to her on December 1, 2025, and the award values will be prorated to reflect the portion of the year during which she will serve on the Board, specifically from October 6, 2025 until the Company’s 2026 annual meeting of stockholders. In addition, Ms. Peacock will be eligible to defer all or any portion of her cash fees and the entire amount of each restricted stock unit grant pursuant to the terms of the Company’s Director Deferred Compensation Plan.
On October 7, 2025, the Company issued a press release regarding Ms. Peacock’s election to the Board. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits |
The following exhibit relating to Item 5.02 shall be deemed to be furnished, and not filed.
| 99.1 | Press Release entitled “IDEXX Laboratories Elects Karen Peacock to Board of Directors” dated October 7, 2025. |
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document) |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IDEXX LABORATORIES, INC. | ||
| Date: October 7, 2025 | By: | /s/ Sharon E. Underberg |
| Sharon E. Underberg | ||
| Executive Vice President, General Counsel and Corporate Secretary | ||
3
FAQ
Who was elected to the IDEXX (IDXX) Board of Directors?
When was the director election disclosed by IDEXX (IDXX)?
What exhibit was attached to the IDEXX 8-K filing?
Who signed the IDEXX 8-K filing for the director election?
Does the filing include Karen Peacock's background or committee assignments?
